Oral modified-release formulations in motion: The relationship between gastrointestinal transit and drug absorption

International Journal of Pharmaceutics

Volumn 395, Issue 1-2, 2010, Pages 26-36

  Varum, Felipe J O ^a   Merchant, Hamid A ^a   Basit, Abdul W ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Bioavailability; Biopharmaceutics; Colonic delivery; Controlled release; Delayed release; Enteric coatings; Gamma scintigraphy; Gastrointestinal transit; Multiparticulates; Multiple units; Pharmacokinetics; Single units

Indexed keywords

ACETYLSALICYLIC ACID; BUDESONIDE; DICLOFENAC; DIDANOSINE; DILTIAZEM; DOMPERIDONE; ERYTHROMYCIN; ITOPRIDE; LANSOPRAZOLE; METFORMIN; PROKINETIC AGENT; TD 5108; TEGASEROD; THEOPHYLLINE; UNCLASSIFIED DRUG; VELUSETRAG; DELAYED RELEASE FORMULATION; ENTERIC COATED TABLET;

AREA UNDER THE CURVE; CONTROLLED RELEASE FORMULATION; DELAYED RELEASE FORMULATION; DRUG ABSORPTION; DRUG FORMULATION; ENTERIC COATED TABLET; GASTROINTESTINAL TRANSIT; HUMAN; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING; SUSTAINED RELEASE FORMULATION; BIOAVAILABILITY; DRINKING; DRUG ADMINISTRATION; EATING; FEEDING BEHAVIOR; INTESTINE ABSORPTION; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRINKING; DRUG ADMINISTRATION SCHEDULE; EATING; FEEDING BEHAVIOR; GASTROINTESTINAL TRANSIT; HUMANS; INTESTINAL ABSORPTION; PHARMACOKINETICS; TABLETS, ENTERIC-COATED;

EID: 77954315812     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.04.046     Document Type: Review

References (94)

1. Abrahamsson B., Alpsten M., Jonsson U.E., Lundberg P.J., Sandberg A., Sundgren M., Svenheden A., Tolli J. Gastro-intestinal transit of a multiple-unit formulation (metoprolol CR/ZOK) and a non-disintegrating tablet with the emphasis on colon. Int. J. Pharm. 1996, 140:229-235.
2. Adkin D.A., Davis S.S., Sparrow R.A.D.H.P., Phillips A.J., Wilding I.R. The effects of pharmaceutical excipients on small intestinal transit. Br. J. Clin. Pharmacol. 1995, 39:381-387.
3. Ashiru D.A.I., Patel R., Basit A.W. Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not in females. Pharm. Res. 2008, 25:2327-2333.
4. Basit A.W., Newton J.M., Short M.D., Waddington W.A., Ell P.J., Lacey L.F. The effect of Polyethylene Glycol 400 on gastrointestinal transit: implications for the formulation of poorly-water soluble drugs. Pharm. Res. 2001, 18:1146-1150.
5. Basit A.W., Podczeck F., Newton J.M., Waddington W.A., Ell P.J., Lacey L.F. The use of formulation technology to assess regional gastrointestinal drug absorption in humans. Eur. J. Pharm. Sci. 2004, 21:179-189.
6. Basit A.W., Short M.D., Mcconnell E.L. Microbiota-triggered colonic delivery: robustness of the polysaccharide approach in the fed state in man. J. Drug Target. 2009, 17:64-71.
7. Bechgaard H., Nielsen G.H. Controlled-release multiple-units and single-units doses. Drug Dev. Ind. Pharm. 1978, 4:53-67.
8. Bechgaard H., Brodie R.R., Chasseaud L.F., Houmoller P., Hunter J.O., Siklos P., Taylor T. Bioavailability of indomethacin from two multiple-units controlled-release formulations. Eur. J. Clin. Pharmacol. 1982, 21:511-515.
9. Brunner M., Ziegler S., Di Stefano A.F.D., Dehghanyar P., Kletter K., Tschurlovits M., Villa R., Bozzella R., Celasco G., Moro L., Rusca A., Dudczak R., Müller M. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br. J. Clin. Pharmacol. 2005, 61:31-38.
10. Chaw C.S., Yazaki E., Evans D.F. The effect of pH change on the gastric emptying of liquids measured by electrical impedance tomography and pH-sensitive radiotelemetry capsule. Int. J. Pharm. 2001, 227:167-175.
11. Chen M.-L., Straughn A.B., Sadrieh N., Meyer M., Faustino P.J., Ciavarella A.B., Meibohm B., Yates C.R., Hussain A.S. A modern view of excipient effects on bioequivalence: case study of sorbitol. Pharm. Res. 2007, 24:73-80.
12. Choe S.Y., Neudeck B.L., Welage L.S., Amidon G.E., Barnett J.L., Amidon G.L. Novel method to assess gastric emptying in humans: the pellet gastric emptying test. Eur. J. Pharm. Sci. 2001, 14:347-353.
13. Chun A.H., Erdman K., Chiu Y.L., Pilmer B.L., Achari R., Cavanaugh J.H. Bioavailability of lansoprazole granules administered in juice or soft food compared with the intact capsule formulation. Clin. Ther. 2002, 24:1322-1331.
14. Clarke G.M., Newton J.M., Short M.B. Gastrointestinal transit of pellets of differing size and density. Int. J. Pharm. 1993, 100:81-95.
15. Clarke G.M., Newton J.M., Short M.B. Comparative gastrointestinal transit of pellet systems of varying density. Int. J. Pharm. 1995, 114:1-11.
16. Cnota P.J., Nowak H., Tagarro I., Erb K., Schürer M., Schulz H.-U., Maus J. Tramadol SR formulations: Pharmacokinetic comparison of a multiple-units dose (capsule) versus a single-unit dose (tablet). Clin. Drug Invest. 2005, 25:435-443.
17. Corá L.A., Américo M.F., Romeiro F.G., Oliveira R.B., Miranda J.R.A. Pharmaceutical applications of AC Biosusceptometry. Eur. J. Pharm. Biopham. 2010, 74:67-77.
18. Coupe A.J., Davis S.S., Wilding I.R. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm. Res. 1991, 8:360-364.
19. Coupe A.J., Davis S.S., Evans D.F., Wilding I.R. Nocturnal scintigraphic imaging to investigate the gastrointestinal transit of dosage forms. J. Controlled Release 1992, 20:155-162.
20. Coupe A.J., Davis S.S., Evans D.F., Wilding I.R. The effect of sleep on the gastrointestinal transit of pharmaceutical dosage forms. Int. J. Pharm. 1992, 78:69-76.
21. Coupe A.J., Davis S.S., Evans D.F., Wilding I.R. Do pellet formulations empty from the stomach with food?. Int. J. Pharm. 1993, 92:167-175.
22. Damle B., Kaul S., Behr D., Knupp C. Bioequivalence of two formulations of didanosine, encapsulated enteric coated beads and buffered tablet, in healthy volunteers and HIV-infected subjects. J. Clin. Pharmacol. 2002, 42:791-797.
23. Damle B., Ullah I., Doll W., Wiley G., Knupp C. Pharmacokinetics and gamma scintigraphy evaluation of two enteric coated formulations of didanosine in healthy volunteers. Br. J. Clin. Pharmacol. 2002, 54:255-261.
24. Davis S.S., Hardy J.G., Taylor M.J., Whalley D.R., Wilson C.G. The effect of food on the gastrointestinal transit of pellets and an osmotic device (Osmet). Int. J. Pharm. 1984, 21:331-340.
25. Davis S.S., Hardy J.G., Taylor M.J., Whalley D.R., Wilson C.G. A comparative study of the gastrointestinal transit of a pellet and tablet formulation. Int. J. Pharm. 1984, 21:167-177.
26. Davis S.S., Hardy J.G., Fara J.W. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986, 27:886-892.
27. Davis S.S., Robertson, Wilding I.R. Gastrointestinal transit of a multiparticulate tablet formulation in patients with active ulcerative colitis. Int. J. Pharm. 1991, 68:199-204.
28. Davis S.S. Formulation strategies for absorption windows. Drug Discov. Today 2005, 10:249-257.
29. Degen L., Petrig C., Studer D., Schroller S., Beglinger C. Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol. Motil. 2005, 17:821-826.
30. Delhotal-Landes B., Flouvat B., Boutin M.-S., Karpouzas I., Prinseau J. Influence of food on the absorption of theophylline administered in the form of sustained release tablet and microgranules. Biopharm. Drug Dispos. 1988, 9:19-29.
31. Digenis G.A., Sandefer E.P., Parr A.F., Beihn R., McClain C., Scheinthal B.M., Ghebre-Sellassie I., Nesbitt R.U., Randinitis E. Gastrointestinal behaviour of orally administered radiolabelled erythromycin pellets in man as determined by gamma scintigraphy. J. Clin. Pharmacol. 1990, 30:621-631.
32. Edgar B., Bogentoft C., Lagerström P.-O. Comparison of two enteric-coated acetylsalicylic acid preparations by monitoring steady-state levels of salicylic acid and its metabolites in plasma and urine. Biopharm. Drug Dispos. 1984, 5:251-260.
33. Edsbäcker S., Bengtsson B., Larsson P., Lundin P., Nilsson Å., Ulmius J., Wollmer P. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. Aliment. Pharmacol. Ther. 2003, 17:525-536.
34. Efentakis M., Koutlis A., Vlachou M. Development and evaluation of oral multiple-unit and single-unit hydrophilic controlled-release systems. AAPS PharmSciTech 2000, 1.
35. Fadda H.M., McConnell E.L., Short M.D., Basit A.W. Meal-induced acceleration of tablet transit through the human small intestine. Pharm. Res. 2009, 26:356-360.
36. Fallingborg J., Christensen L.A., Ingeman-Nielsen M., Jacobsen B.A., Abildgaard K., Rasmussen H.H. pH profile and regional transit times of the normal gut measured by radiotelemetry device. Aliment. Pharmacol. Ther. 1989, 3:605-613.
37. Fallingborg J., Pedersen P., Jacobsen B.A. Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn's disease. Dig. Dis. Sci. 1998, 43:702-705.
38. Follonier N., Doelker E. Biopharmaceutical comparison of oral multiple-unit and single-unit sustained-release dosage forms. STP Pharma. Sci. 1992, 2:141-158.
39. Garbacz G., Wedemeyer R.S., Nagel S., Giessmann T., Monnikes H., Wilson C.G., Siegmund W., Weitschies W. Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stress. Eur. J. Pharm. Biopharm. 2008, 70:421-428.
40. Goodman K., Hodges L.A., Band J., Stevens H.N.E., Weitschies W., Wilson C.G. Assessing gastrointestinal motility and disintegration profiles of magnetic tablets by a novel magnetic imaging device and gamma scintigraphy. Eur. J. Pharm. Biopham. 2010, 74:84-92.
41. Graffner C., Josefsson K., Stockman O. Intra- and intersubject variation of erythromycin absorption from single-unit and multiple-unit enteric-coated products. Biopharm. Drug Dispos. 1986, 7:163-171.
42. Green D.M. Tablets of coated aspirin microspherules-a new dosage form. J. New Drugs 1966, 6:294-304.
43. Haggard H.W., Greenberg L.A. The influence of certain fruit juices on gastric function. Am. J. Dig. Dis. 1941, 8:163-170.
44. Hardy J.G., Healey J.N.C., Reynolds J.R. Evaluation on an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 1987, 1:273-280.
45. Hebden J.M., Blackshaw P.E., Perkins A.C., Wilson C.G., Spiller R.C. Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment. Pharmacol. Ther. 2000, 14:155-161.
46. Hinton J.M., Lennard-Jones J.E., Young A.C. A new method for studying gut transit times using radioparque markers. Gut 1969, 10:842-847.
47. Hu L.-D., Yang L., Tang X., Zhang Q. Preparation and in vitro/in vivo evaluation of sustained-release metformin hydrochloride pellets. Eur. J. Pharm. Biopharm. 2006, 64:185-192.
48. Hunt J.N., Stubbs D.F. The volume and energy content of meals as determinants of gastric emptying. J. Physiol. 1975, 245:209-225.
49. Hunt J.N., Cash R., Newland P. Energy density of food, gastric emptying, and obesity. Am. J. Clin. Nutr. 1978, 31:S259-S260.
50. Hunt J.N. Mechanisms and disorders of gastric emptying. Ann. Rev. Med. 1983, 34:219-229.
51. Ibekwe V.C., Liu F., Fadda H.M., Khela M.K., Evans D.F., Parsons G.E., Basit A.W. An investigation into the in vivo performance variability of pH responsive polymers for ileo-colonic drug delivery using gamma-scintigraphy in humans. J. Pharm. Sci. 2006, 95:2760-2766.
52. Ibekwe V.C., Khela M.K., Evans D.F., Basit A.W. A new concept in colonic drug targeting: a combined pH-responsive and bacterially-triggered drug delivery technology. Aliment. Pharmacol. Ther. 2008, 28:911-916.
53. Ibekwe V.C., McConnell E.L., Fadda H.M., Khela M.K., Evans D.F., Basit A.W. Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharm. Res. 2008, 25:1828-1835.
54. Kellow J.E., Borody T.J., Phillips S.F., Tucker R.L., Haddad A.C. Human interdigestive motility: variations in patterns from esophagus to colon. Gastroenterology 1986, 91:386-395.
55. Kerlin P., Zinsmeister A.R., Phillips S. Relationship of motility to flow of contents in the human small intestine. Gastroenterology 1982, 82:701-706.
56. Khosla R., Feely L.C., Davis S.S. Gastrointestinal transit of non-disintegrating tablets in fed subjects. Int. J. Pharm. 1989, 53:107-117.
57. Koch K.M., Parr A.F., Tomlinson J.J., Sandefer E.P., Digenis G.A., Donn K.H., Powell J.R. Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit-time. Pharm. Res. 1993, 10:1027-1030.
58. Larouche J., Morais J., Picard M., Lambert C., Spénard J., Landriault H., Kennedy G., Poitras P. Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine. Aliment. Pharmacol. Ther. 1995, 9:315-320.
59. Maddern G.J., Horowitz M., Hetzel D.J., Jamieson Altered solid and liquid gastric emptying in patients with duodenal ulcer disease. Gut 1985, 26:689-693.
60. Manini M.L., Camilleri M., Goldberg M., Sweetser S., McKinzie S., Burton D., Wong S., Kitt M.M., Li Y.P., Zinsmeister A.R. Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol. Motil. 2010, 22:42-49.
61. Marathe P.H., Wen Y., Norton J., Greene D.S., Barbhaiya R.H., Wilding I.R. Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br. J. Clin. Pharmacol. 2000, 50:325-332.
62. Marvola M., Kannikoski A., Aito H., Nykänen S. The effect of food on gastrointestinal transit and drug absorption of a multiparticular sustained-release verapamil formulation. Int. J. Pharm. 1989, 53:145-155.
63. Matuchansky C., Huet P.M., Mary J.Y., Rambaud J.C., Bernier J.-J. Effects of cholecystokinin and metoclopramide on jejunal movements of water and electrolytes on transit time of luminal fluid in man. Eur. J. Clin. Invest. 1972, 2:169.
64. McConnell E.L., Fadda H.M., Basit A.W. Gut instincts: explorations in intestinal physiology and drug delivery. Int. J. Pharm. 2008, 364:213-226.
65. McConnell E.L., Short M.D., Basit A.W. An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man. J. Controlled Release 2008, 130:154-160.
66. Metcalf A.M., Phillips S.F., Zinsmeister A.R., MacCarty R.L., Beart R.W., Wolff B.G. Simplified assessment of segmental colonic transit. Gastroenterology 1987, 92:40-47.
67. Munkholm P., Langholz E., Davidsen M., Binder V. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993, 105:1716-1723.
68. Olsson C., Holmgren S. The control of gut motility. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 2001, 128:481-503.
69. Podczeck F., Course N.C., Newton J.M., Short M.B. The influence of non-disintegrating tablet dimensions and density on their gastric emptying in fasted volunteers. J. Pharm. Pharmacol. 2007, 59:23-27.
70. Price J.M.C., Davis S.S., Sparrow R.A., Wilding I.R. The effect of meal composition on the gastrocolonic response: implications for drug delivery to the colon. Pharm. Res. 1993, 10:722-726.
71. Rasmussen L., Øster-JØrgensen E., Qvist N., Pedersen S.A. The effects of omeprazole on intragastric pH, intestinal motility, and gastric emptying rate. Scand. J. Gastroenterol. 1999, 34:671-675.
72. Richardson J.C., Bowtell R.W., Mäder K., Melia C.D. Pharmaceutical applications of magnetic resonance imaging (MRI). Adv. Drug Deliv. Rev. 2005, 57:1191-1209.
73. Sadik R., Abrahamsson H., Stotzer P.O. Gender differences in gut transit shown with a newly developed radiological procedure. Scand. J. Gastroenterol. 2003, 38:36-42.
74. Sathyan G., Hwang S., Gupta S.K. Effect of dosing time on the total intestinal transit time of non-disintegrating systems. Int. J. Pharm. 2000, 204:47-51.
75. Schiller C., Frohlich C.P., Giessmann T., Siegmund W., Mönnikes H., Hosten N., Weitschies W. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic ressonance imaging. Aliment. Pharmacol. Ther. 2005, 22:971-979.
76. Schulze J.D.R., Waddington W.A., Ell P.J., Parsons G.E., Coffin M.D., Basit A.W. Concentration-dependent effects of polyethylene glycol on gastrointestinal transit and drug absorption. Pharm. Res. 2003, 20:1984-1988.
77. ®. Eur. J. Clin. Pharmacol. 1984, 26:405-407.
78. Smith H.J., Feldman M. Influence of food and marker length on gastric emptying of indigestible radiopaque markers in healthy humans. Gastroenterology 1986, 91:1452-1455.
79. Stephen A., Wiggins H.S., Englyst H.N., Cole T.J., Wayman B.J., Cummings J.H. The effect of age, sex and level of intake of dietary fibre from wheat on large-bowel function in thirty healthy subjects. Br. J. Nutr. 1986, 56:349-361.
80. Sugito K., Hiroyasu O., Goto H., Noguchi M., Kogure T., Takano M., Maruyama Y., Sasaki Y. Gastrointestinal transit of non-disintegrating solid formulations in humans. Int. J. Pharm. 1990, 60:89-97.
81. Tuleu C., Basit A.W., Waddington W.A., Ell P.J., Newton J. Colonic delivery of 4-aminosalicylic acid using amylose-ethylcellulose-coated hydroxypropylmethylcellulose capsules. Aliment. Pharmacol. Ther. 2002, 16:1771-1779.
82. Tursi A., Brandimarte G., Giorgetti G., Nasi G. Assessment of oroceacal transit time in different localization of Crohn's disease and its possible influence on clinical response to therapy. Eur. J. Gastroenterol. Hepatol. 2003, 15:69-74.
83. Varum F.J.O., McConnell E.L., Sousa J.J.S., Veiga F., Basit A.W. Mucoadhesion and the gastrointestinal tract. Crit. Rev. Ther. Drug Carrier Syst. 2008, 25:207-258.
84. Vassallo M., Camilleri M., Phillips S.F., Brown M.L., Chapman N.J., Thomforde G.M. Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology 1992, 102:102-108.
85. Waterman K.C. A critical review of gastric retentive controlled drug delivery. Pharm. Dev. Technol. 2007, 121:1-10.
86. Weitschies W., Kosch O., Mönnikes H., Trahms L. Magnetic Marker Monitoring: an application of biomagnetic measurement instrumentation and principles for the determination of the gastrointestinal behavior of magnetically marked solid dosage forms. Adv. Drug Deliv. Rev. 2005, 57:1210-1222.
87. Weitschies W., Blume H., Mönnikes H. Magnetic marker monitoring: High resolution real time tracking of oral solid dosage forms in the gastrointestinal tract. Eur. J. Pharm. Biopham. 2010, 74:93-101.
88. Wilding I.R., Hardy J.G., Sparrow R.A., Davis S.S., Daly P.B., English J.R. In vivo evaluation of an enteric-coated naproxen tablets using gamma scintigraphy. Pharm. Res. 1992, 9:1436-1441.
89. Wilding I.R. Scintigraphic evaluation of colonic delivery systems. STP Pharma Sci. 1995, 5:13-18.
90. ®) diltiazem formulation. J. Controlled Release 1995, 33:89-97.
91. Wilding I.R., Kenyon C.J., Hooper G. Gastrointestinal spread of oral prolonged-release, mesalazine microgranules (Pentasa) dosed as either tablets or sachet. Aliment. Pharmacol. Ther. 2000, 14:163-169.
92. Wilding I.R., Coupe A.J., Davis S.S. The role of gamma-scintigraphy in oral drug delivery. Adv. Drug Deliv. Rev. 2001, 46:103-124.
93. Wilding I.R., Behrens C., Tardif S.J., Wray H., Bias P., Albrecht W. Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. Aliment. Pharmacol. Ther. 2003, 17:1153-1162.
94. Wilson C.G., Washington N. Assessment of disintegration and dissolution of dosage forms in vivo using gamma scintigraphy. Drug Dev. Ind. Pharm. 1988, 14:211-281.